Physician profile
Robert A Koppel
NPI 1326066952
$212,364.96
in general payments reported to CMS, 2019-2025
45 companies · $23K in 2025
The $23K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $7,939 · 2021: $27K · 2022: $57K · 2023: $55K · 2024: $26K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Travel and Lodging: $12K · Food and Beverage: $11K · Consulting Fee: $4,673 · Education: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,681.25 |
| Travel and Lodging | $12,032.96 |
| Food and Beverage | $10,982.08 |
| Consulting Fee | $4,672.50 |
| Education | $424.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $163,154.16 | 2021-2025 | Opzelura, Opzelura |
| Pfizer INC. | $17,568.94 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12,059.19 | 2019-2023 | Duobrii, Arazlo |
| Janssen Biotech, INC. | $3,746.40 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $3,397.74 | 2022-2025 | Sotyktu |
| Abbvie INC. | $2,193.51 | 2019-2025 | |
| Genzyme Corporation | $1,440.30 | 2019-2025 | |
| Amgen INC. | $1,160.74 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $1,114.85 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $894.44 | 2019-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $815.27 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $735.66 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Leo Pharma INC. | $667.66 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $556.35 | 2020-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $482.12 | 2023-2025 | Zoryve |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $337.06 | 2019-2025 | |
| Almirall LLC | $308.36 | 2019-2025 | Klisyri, Seysara |
| Genentech USA, INC. | $193.54 | 2019-2022 | |
| Dermavant Sciences, INC. | $179.72 | 2023-2024 | Vtama |
| Allergan, INC. | $165.13 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $135.10 | 2020-2021 | |
| Epi Health, LLC | $127.60 | 2019-2022 | |
| Revance Therapeutics, INC. | $98.61 | 2024 | Daxxify |
| Galderma Laboratories, L.P. | $95.93 | 2019-2025 | Nemluvio |
| Medimetriks Pharmaceuticals, INC. | $91.65 | 2021-2025 | Neo-Synalar |
| Sanofi-Aventis U.S. LLC | $86.50 | 2021-2023 | |
| Organon LLC | $77.03 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.28 | 2022-2024 | Spevigo |
| Celgene Corporation | $58.60 | 2019 | |
| Merz North America, INC. | $57.11 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $53.61 | 2024 | Acthar |
| Biofrontera INC. | $39.45 | 2024-2025 | Ameluz, Rhodoled Xl, Xepi |
| Organogenesis INC. | $38.60 | 2021-2024 | |
| Journey Medical Corporation | $37.50 | 2019 | |
| Kerecis Limited | $26.33 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Botanix Sb INC | $22.10 | 2025 | Sofdra |
| Dermira, INC. | $18.53 | 2019 | |
| Verrica Pharmaceuticals INC. | $17.87 | 2023 | Ycanth |
| Hill Dermaceuticals, INC. | $16.55 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Mission Pharmacal Company | $11.98 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $8.72 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Koppel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.